Copanlisib*
Clinical Trials

Learn about ongoing studies
investigating patients with relapsed/refractory indolent
non-Hodgkin's lymphoma (iNHL).
  • *Copanlisib is being investigated for uses that are not approved by the FDA, the EMA, or other health authorities.
  • You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
    For Bayer products you can report these directly to Bayer by clicking here.